[go: up one dir, main page]

RU2002111413A - Imidazole derivatives as phosphodiesterase VII inhibitors - Google Patents

Imidazole derivatives as phosphodiesterase VII inhibitors

Info

Publication number
RU2002111413A
RU2002111413A RU2002111413/14A RU2002111413A RU2002111413A RU 2002111413 A RU2002111413 A RU 2002111413A RU 2002111413/14 A RU2002111413/14 A RU 2002111413/14A RU 2002111413 A RU2002111413 A RU 2002111413A RU 2002111413 A RU2002111413 A RU 2002111413A
Authority
RU
Russia
Prior art keywords
disorders
phosphodiesterase vii
vii inhibitors
cachexia
sepsis
Prior art date
Application number
RU2002111413/14A
Other languages
Russian (ru)
Other versions
RU2259199C2 (en
Inventor
Ханс Михаэль ЭГГЕНВАЙЛЕР
Рохус ЙОНАС
Михаэль Вольф
Михаэль ГАССЕН
Оливер ПЕШКЕ
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19950647A external-priority patent/DE19950647A1/en
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of RU2002111413A publication Critical patent/RU2002111413A/en
Application granted granted Critical
Publication of RU2259199C2 publication Critical patent/RU2259199C2/en

Links

Claims (3)

1. Применение соединений формулы I1. The use of compounds of formula I
Figure 00000001
Figure 00000001
 в которой R1 представляет собой Н, А, бензил, индан-5-ил, 1,2,3,4-тетрагидронафтален-5-ил, дибензотиофен-2-ил, или фенил, который незамещен или моно-, ди- или тризамещен Hal, A, A-CO-NH, бензилокси, алкокси, СООН или СООА;in which R 1 represents H, A, benzyl, indan-5-yl, 1,2,3,4-tetrahydronaphthalen-5-yl, dibenzothiophen-2-yl, or phenyl, which is unsubstituted or mono-, di- or trisubstituted Hal, A, A-CO-NH, benzyloxy, alkoxy, COOH or COOA; R2 представляет собой Н или А;R 2 represents H or A; Х представляет собой О или S;X represents O or S; Hal представляет собой F, Cl, Br или I;Hal represents F, Cl, Br or I; А представляет собой алкил, имеющий от 1 до 6 атомов С,A is an alkyl having from 1 to 6 C atoms, а также их физиологически приемлемых солей и/или сольватов в качестве ингибиторов фосфодиэстеразы VII.as well as their physiologically acceptable salts and / or solvates as phosphodiesterase VII inhibitors. 2. Применение соединений формулы I по п.1 и/или их физиологически приемлемых солей или сольватов для получения фармацевтического препарата для контролирования аллергических расстройств, астмы, хронического бронхита, атопического дерматита, псориаза и других кожных нарушений, воспалительных расстройств, автоиммунных заболеваний, таких как, например, ревматоидный артрит, рассеянного склероза, болезни Крона, сахарного диабета или язвенного колита, остеопороза, реакции отторжения трансплантатов, кахексии, роста опухолей или метастаз опухолей, сепсиса, нарушений памяти, атеросклероза и СПИДа.2. The use of the compounds of formula I according to claim 1 and / or their physiologically acceptable salts or solvates for the manufacture of a pharmaceutical preparation for controlling allergic disorders, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin disorders, inflammatory disorders, autoimmune diseases, such as for example, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, diabetes mellitus or ulcerative colitis, osteoporosis, graft rejection reactions, cachexia, tumor growth, or tumor metastases s, sepsis, memory disorders, atherosclerosis and AIDS. 3. Применение ингибиторов фосфодиэстеразы VII для получения фармацевтического препарата для контролирования аллергических расстройств, астмы, хронического бронхита, атонического дерматита, псориаза и других кожных нарушений, воспалительных расстройств, автоиммунных заболеваний, таких как, например, ревматоидный артрит, рассеянного склероза, болезни Крона, сахарного диабета или язвенного колита, остеопороза, реакции отторжения трансплантатов, кахексии, роста опухолей или метастаз опухолей, сепсиса, нарушений памяти, атеросклероза и СПИДа.3. The use of phosphodiesterase VII inhibitors for the manufacture of a pharmaceutical preparation for the control of allergic disorders, asthma, chronic bronchitis, atonic dermatitis, psoriasis and other skin disorders, inflammatory disorders, autoimmune diseases, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, sugar diabetes or ulcerative colitis, osteoporosis, graft rejection reactions, cachexia, tumor growth or tumor metastases, sepsis, memory impairment, atherosclerosis and STI Yes.
RU2002111413/15A 1999-10-21 2000-10-10 Derivatives of imidazole as inhibitors of phosphodiesterase vii RU2259199C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19950647A DE19950647A1 (en) 1999-10-21 1999-10-21 Benzopyranoimidazolone and benzothiopyranoimidazolone derivatives as phosphodiesterase-VII inhibitors useful for treatment of e.g. asthma, psoriasis, osteoporosis, cachexia, sepsis, tumors and AIDS
DE19950647.7 1999-10-21

Publications (2)

Publication Number Publication Date
RU2002111413A true RU2002111413A (en) 2003-11-20
RU2259199C2 RU2259199C2 (en) 2005-08-27

Family

ID=7926352

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002111413/15A RU2259199C2 (en) 1999-10-21 2000-10-10 Derivatives of imidazole as inhibitors of phosphodiesterase vii

Country Status (22)

Country Link
EP (1) EP1222193B1 (en)
JP (1) JP2003512381A (en)
KR (1) KR20020060201A (en)
CN (1) CN1382146A (en)
AR (1) AR026198A1 (en)
AT (1) ATE247121T1 (en)
AU (1) AU780788B2 (en)
BR (1) BR0014922A (en)
CA (1) CA2388314C (en)
CZ (1) CZ293751B6 (en)
DE (2) DE19950647A1 (en)
DK (1) DK1222193T3 (en)
ES (1) ES2200957T3 (en)
HU (1) HUP0203139A3 (en)
MX (1) MXPA02003952A (en)
NO (1) NO20021846L (en)
PL (1) PL355020A1 (en)
PT (1) PT1222193E (en)
RU (1) RU2259199C2 (en)
SK (1) SK4922002A3 (en)
WO (1) WO2001029049A2 (en)
ZA (1) ZA200203995B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294189T3 (en) * 2001-12-13 2008-04-01 Asubio Pharma Co., Ltd. DERIVATIVES OF PIRAZOLOPIRIMIDINONA THAT HAVE INHIBITING ACTION OF PDE7.
DE10163991A1 (en) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
JP2006219373A (en) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pyridinylpyrazolopyrimidinone derivatives having PDE7 inhibitory action
JP2006219374A (en) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Imidazotriazinone derivatives having PDE7 inhibitory action
CA2569530C (en) 2004-07-01 2013-07-30 Daiichi Asubio Pharma Co.,Ltd. Thienopyrazole derivative having pde 7 inhibitory activity
MX2009010450A (en) 2007-03-27 2009-11-23 Omeros Corp The use of pde7 inhibitors for the treatment of movement disorders.
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2817071C (en) 2010-11-08 2018-04-24 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
EP4572766A1 (en) 2022-08-18 2025-06-25 Mitodicure GmbH Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4305954A (en) * 1981-02-11 1981-12-15 E. I. Du Pont De Nemours And Company Antiinflammatory 3,4-dihydro(or 1,4-dihydro)-2-[(substituted)thio]-[1]benzopyrano[3,4-d]imidazoles and their corresponding sulfoxides and sulfones
ATE178330T1 (en) * 1993-08-19 1999-04-15 Janssen Pharmaceutica Nv VASOCONTRACTING SUBTITUTED DIHYDROPYRANOPYRIDINES
DE19632423A1 (en) * 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidines
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
WO2000023091A2 (en) * 1998-10-15 2000-04-27 Bioimage A/S Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases
WO2000068230A1 (en) * 1999-05-05 2000-11-16 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors

Similar Documents

Publication Publication Date Title
RU2002113750A (en) Derivatives of pyrrole as phosphodiesterase VII inhibitors
RU2002111413A (en) Imidazole derivatives as phosphodiesterase VII inhibitors
RU2403251C2 (en) 2,4-di(hetero)arylaminopyrimidine derivatives as zap-70 inhibitors
RU2004129768A (en) Bicyclic Pyridines and Pyrimidines as P38 Kinase Inhibitors
RU2007141892A (en) 5-METHYL-1- (SUBSTITUTED PHENYL) -2- (1H) -PYRIDONE FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF FIBROSIS IN ORGANS AND TISSUES
JP2002515400A (en) Certain diarylimidazole derivatives; a new class of NPY-specific ligands
RU2002113746A (en) Isoxazole derivatives as phosphodiesterase VII inhibitors
EP0437103A3 (en) Substituted 5-(alkyl)carboxamide imidazoles
CA2463102A1 (en) Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
SI1622610T1 (en) 1-(2h-pyrazol-3-yl)-3-(4-(1-(benzoyl)-piperidin-4-ylmethyl)-phenyl)-urea derivatives and related compounds as inhibitors of p38 kinase and/or tnf inhibitors for the treatment of inflammations
RU2002113759A (en) Imidazole compounds as phosphodiesterase VII inhibitors
JP2002527414A5 (en)
JPH10101672A (en) Adenosine enhancer
KR880013959A (en) Phosphorus-Containing HMG-CoA Reductase Inhibitors, New Intermediates and Methods
CA2099867A1 (en) 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
CN102307861B (en) Phenylimidazole compounds
JP6814794B2 (en) A novel compound having BLT inhibitory activity and a composition for preventing or treating inflammatory diseases containing the same as an active ingredient.
RU2001111323A (en) DERIVATIVES 2-PHENILPIRAN-4-SHE
US20050182119A1 (en) Substituted pyrazoline derivatives
RU99105208A (en) PHARMACEUTICAL COMPOSITION CONTAINING 4-OXUBUTANE ACIDS
RU2004104945A (en) 4- (BENZYLIDENAMINO) -3- (METHYLSULFANIL) -4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES HAVING AN INHIBITING EFFECT WITH RESPECT TO PHOSPHODESTERESIS IV AND CREDIT ANTOGENES
RU2005111220A (en) 6,7-DIHYDRO-5H-PYRAZOLO [1,2-A] PYRAZOL-1-ONE, REGULATING INFLAMMATORY CYTOKINES
KR20070089829A (en) Pyrimidinylisoxazole Derivatives
RU98118188A (en) RETROAMIDE-CONTAINING DERIVATIVES AS ENDOTELIN-CONVERTER ENZYME INHIBITORS
RU2006138424A (en) NEW DIAZINE DERIVATIVES, THEIR PRODUCTION AND APPLICATION AS PHARMACEUTICAL AGENTS